Second-Generation Trabecular Micro-Bypass Stents as Standalone Treatment for Glaucoma: A 36-Month Prospective Study

ConclusionThis real-world cohort of glaucomatous eyes with substantial preoperative disease burden experienced significant, sustained, safe IOP and medication reductions through 36  months following stand-alone iStentinject implantation.FundingArticle processing charges and writing assistance were provided by Glaukos Corp. (San Clemente, CA, USA).
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research